GenesisCare will expand testing for prostate cancer nationwide with the use of Pylarify (F-18 DCFPyL), a PET radiopharmaceutical designed to target prostate-specific membrane antigen (PSMA).
Pylarify received approval from the U.S. Food and Drug Administration in May, 2021.
GenesisCare will expand access to the radiotracer at its Florida, South Carolina, and Texas centers, the company said.
The first Pylarify injection in a patient at a GenesisCare site took place on June 3, 2021, the company added.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
